In recent years, Chinese medicine has unique advantages in preventing and treating various diseases and microbial drug resistance. Including its function of resisting COVID-19 cell injury and repairing inflammation, which makes Chinese medicine get more and more attention. In addition, the state is fully supporting the development of the Chinese medicine industry, and there is still room for growth in the Chinese medicine industry.
With the aging of population and the increase of per capita income of residents, people are paying more and more attention to health, which brings continuous growth space to the pharmaceutical market. Moreover, the role of Chinese medicine in health care, chronic diseases and disease prevention can be said to be very obvious. For example, chronic diseases such as cardiovascular and cerebrovascular diseases and diabetes, which are common in the elderly, will directly lead to an increase in the demand for traditional Chinese medicine.
Steady rise
On the whole, thanks to the steady growth of market demand and the strong support of the state, the development prospect of Chinese medicine industry will be higher and higher in the future. Yiling Pharmaceutical's main business is the research and development, production and sales of patented innovative Chinese medicine. The company is a top Chinese medicine 10 enterprise in China, a top 20 listed pharmaceutical companies in China and a top 500 listed companies in China. He has won more than 30 national, provincial and ministerial science and technology awards such as the first prize of national scientific and technological progress, the second prize of national scientific and technological progress and the second prize of national technological invention.
Under the guidance of the innovative collateral disease theory, Yiling Pharmaceutical focuses on six diseases with high incidence and large market consumption, such as cardiovascular and cerebrovascular diseases, diabetes, respiratory diseases, tumors, neurological and urinary diseases, with the traditional Chinese medicine research and development assembly line as the core. Develop a series of patented traditional Chinese medicines with independent intellectual property rights, and directly create unique product layout advantages in the pharmaceutical industry. Continue to maintain a leading position in the field of cardiovascular and cerebrovascular diseases and cold respiratory diseases.